Cytotoxic drug residues in urine of dogs receiving anticancer chemotherapy

Journal of Veterinary Internal Medicine

Volumn 24, Issue 2, 2010, Pages 384-390

  Knobloch, A ^a   Mohring, S A I ^a   Eberle, N ^a   Nolte, I ^a   Hamscher, G ^a   Simon, D ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Canine; Health risk; Occupational hazard; Tumor therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESIDUE; VINBLASTINE; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; DOG; DOG DISEASE; ENVIRONMENTAL EXPOSURE; LYMPHOMA; SARCOMA; URINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; DOXORUBICIN; DRUG RESIDUES; ENVIRONMENTAL EXPOSURE; LYMPHOMA; MAST-CELL SARCOMA; VINBLASTINE; VINCRISTINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 77649110094     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0453.x     Document Type: Article

References (57)

1. Chun RA, Garrett L, MacEwen E. Cancer chemotherapy. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology, 3rd ed. Philadelphia, PA: WB Saunders; 2001:92-118.
2. Moore MJ, Erlichman E. Pharmacology of anticancer drugs. In: Tannock IF, Hill RP, eds. The Basic Science of Oncology, 3rd ed. New York: McGraw International Editions; 1998:370-373.
3. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985;313:1173-1178.
4. Stucker I, Caillard JF, Collin R, et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990;16:102-107.
5. Waksvik H, Klepp O, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981;65: 607-610.
6. Pohlova H, Cerna M, Rossner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res 1986;174:213-217.
7. Milkovic-Kraus S, Horvat D. Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs. Am J Ind Med 1991;19:771-774.
8. Sardas S, Gok S, Karakaya AE. Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs. Toxicol Lett 1991;55:311-315.
9. Goloni-Bertollo EM, Tajara EH, Manzato AJ, Varella-Garcia M. Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer 1992;50:341-344.
10. Sessink PJ, Cerna M, Rossner P, et al. Urinary cyclophosph-amide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994;309:193-199.
11. Sessink PJM, Boer KA, Scheefhals APH, et al. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992;64:105-112.
12. Ensslin AS, Stoll Y, Pethran A, et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994;51:229-233.
13. Ensslin AS, Huber R, Pethran A, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: Urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997;70:205-208.
14. Burgaz S, Karahalil B, Bayrak P, et al. Urinary cyclophosph-amide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999;439:97-104.
15. Pethran A, Schierl R, Hauff K, et al. Uptake of antineoplastic agents in pharmacy and hospital workers. Part I: Monitoring of urinary concentrations. Int Arch Occup Environ Health 2003;76: 5-10.
16. Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: A pilot study. Ann Occup Hyg 2004;48:237-244.
17. Fransman W, Vermeulen R, Kromhout H. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Environ Health 2005;78: 403-412.
18. Fransman W, Peelen S, Hilhorst S, et al. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann Occup Hyg 2007;51:231-239.
19. ECVIMCA. Preventing occupational and environmental exposure to cytotoxic drugs in veterinary medicine, 2nd version July 2007. Available at: http://www.ecvim-ca.org/guide_lines.html. Accessed May 10, 2009.
20. Dorn CR, Taylor DO, Schneider R, et al. Survey of animal neoplasms in Alameda and contra costa counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-318.
21. Dorn CR, Taylor DO, Schneider R. The epidemiology of canine leukaemia and lymphoma. Bibl Haematol 1970;36:403-415.
22. MacEwen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981;178:1178-1181.
23. Valerius KD, Ogilvie GK, Mallinckrodt CH, Getzy DM. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997;210:512-516.
24. Myers NC III, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
25. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAPL) for dogs with lymphoma. J Vet Intern Med 1998;12:465-470.
26. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
27. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
28. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAPS) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
29. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6 month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
30. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948-954.
31. Priester WA. Skin tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 1973;50:457-466.
32. Vail DM. Mast cell tumors. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology, 2nd ed. Philadelphia, PA: WB Saunders; 1996:192-210.
33. Hottendorf GH, Nielsen SW. Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl Veterinarmed A 1967;14: 272-281.
34. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27-41.
35. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
36. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
37. Davies DR, Wyatt KM, Jardine JE, et al. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004;40:124-130.
38. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587.
39. Camps-Palau MA, Leibman NF, Elmslie R, et al. Treatment of canine mast cell tumors with vinblastine, cyclophosphamide and prednisone: 35 cases. Vet Comp Oncol 2007;5:156-167.
40. Marconato L, Bettini G, Giacoboni C, et al. Clinicopatho-logical features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med 2008;22: 1001-1007.
41. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1390-1396.
42. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-1309.
43. Hamscher G, Mohring SAI, Knobloch A, et al. Determination of drug residues in urine of dogs receiving anti-cancer chemotherapy by LC-ESI-MS-MS: is there an environmental or occupational risk. J Anal Toxicol in press.
44. Knobloch A, Mohring SAI, Eberle N, et al. Drug residues in serum of dogs receiving anti-cancer chemotherapy. J Vet Intern Med in press.
45. DeWerk Neal A, Wadden RA, Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 1983;40:597-601.
46. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 1993;35:57-60.
47. Kromhout H, Hoek F, Uitterhoeve R, et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 2000;44:551-560.
48. Kiffmeyer TK, Kube C, Opiolka S, et al. Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety. Pharmaceut J 2002;268:331-337.
49. Glue P, Clement RP. Cytochrome P450 enzymes and drug metabolism-basic concepts and methods of assessment. Cell Mol Neurobiol 1999;19:309-323.
50. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219-252.
51. Hahn KA, Chan TCK, Morrison WB, Hahn EA. Highperformance liquid chromatographic analysis of doxorubicin and metabolites in canine urine. J Am Anim Hosp Assoc 1994;30:276-280.
52. Erjavec Z, Beijnen JH, Mulder NH. A taste of taxol. J Feline Med Surg 2001;3:35-36.
53. Meijster T, Fransman W, Veldhof R, Kromhout H. Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 2006;50:657-664.
54. IARC. Some aziridines, N-, S- and O-mustards and selenium. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 9, 1975.
55. IARC. Some naturally occurring substances. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 9,1976.
56. IARC Some antineoplastic and immunosuppressive agents. Summary of Data Reported and Evaluation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 26, 1981.
57. IARC Overall evaluations of carcinogenicity: An Updating of IARC Monographs Volumes 1-42. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Suppl. 7, 1987.